Vol 4, No 2 (2019)
Review article
Published online: 2019-03-18

open access

Page views 2275
Article views/downloads 1799
Get Citation

Connect on Social Media

Connect on Social Media

Diagnostic and therapeutic procedures in gout

Rafał Wojciechowski1, Kinga Kościńska-Ilczyszyn1, Marzena Waszczak-Jeka2, Sławomir Jeka3
Medical Research Journal 2019;4(2):95-98.

Abstract

Gout, a rheumatic disease caused by crystals (crystal arthropathy), is a form of inflammatory arthritis caused
by monosodium urate depositing in the synovial fluid and as time goes by outside the joints as well (in
other tissues and organs).Gout attacks are sudden and often result from a dietary mistake. In 2015 the
European and American Rheumatological Associations (EULAR and ACR) published joint classification
criteria for gout. The criteria involve gout-specific clinical symptoms, irregular results of laboratory tests
and lesions visible in imaging tests. The “golden standard” of diagnostics still remains the presence of uric
acid crystals in a sample of synovial fluid, the contents of the bursa and of the gouty tophus. The course of
treatment for patients with gout depends on the stage of the disease, but it comes down to implementing
various forms of preventing hyperuricemia by modifying the patient’s lifestyle and diet, reducing risk factors
(such as overweight and obesity) and pharmacological treatment, both in-between and during attacks.

Article available in PDF format

View PDF Download PDF file

References

  1. Dalbeth N, So A. Hyperuricaemia and gout: state of the art and future perspectives. Ann Rheum Dis. 2010; 69(10): 1738–1743.
  2. Zimmermann-Górska I. Postępowanie diagnostyczno-terapeutyczne w chorobach wywoływanych przez kryształy. Reumatologia. 2012; 50: 177–180.
  3. Neogi T, Jansen TL, Dalbeth N, et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015; 74(10): 1789–1798.
  4. , et alet al.. Arthritis & Rheumatology. 2015; 67(10): 2557–2568.
  5. Maślińska M. Gout and calcium pyrophosphate dihydrate deposition disease. Reumatologia/Rheumatology Supplements. ; 2016: 105–109.
  6. Bridgeman MB, Chavez B. Febuxostat for the treatment of gout. Expert Opin Pharmacother. 2015; 16(3): 395–398.
  7. Zimmermann-Górska I, Tuchocka-Kaczmarek A, Goncerz G. Rozpoznanie i leczenie dny moczanowej. Podsumowanie zaleceń międzynaorodwej grupy reumatologów w ramach inicjatywy 3e. Medycyna Praktyczna. 2014; 5: 61–65.
  8. Zimmermann-Górska I. Dna moczanowa. Interna Szczeklika Gajewski P. (red. Medycyna Praktyczna, Kraków. ; 2018.